Institutional Clinical and Translational Science Award (U54)

The summary for the Institutional Clinical and Translational Science Award (U54) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Institutional Clinical and Translational Science Award (U54): Purpose. This FOA invites current Clinical and Translational Science Award (CTSA) awardees to propose developments in their environments that will sustain and advance clinical and translational science as a distinct discipline. NIH resources will give institutions flexibility to develop their existing configuration, resources and talent to maximize the safety, efficiency, quality and speed of clinical and translational research. The academic home for clinical and translational science can be a center, department, or institute (C/D/I), and is expected to include faculty who conduct original research, develop graduate and postgraduate training curricula and lead programs that integrate clinical and translational science across multiple departments, schools, research institutes and hospitals. Mechanism of Support. This FOA will utilize the NIH Specialized Center Cooperative Agreements (U54) mechanism. Funds Available and Anticipated Number of Awards. The total funds available for the new awards are approximately $116 million. Up to 12 awards are anticipated from this solicitation. The NIH intends to issue solicitations for new and competing renewals of CTSAs annually. Awards will vary in size due to the prior consolidation of multiple programs at the applicant institution(s) into the CTSA program proposal. The annual total costs that may be requested have been communicated with potential applicants and may be verified by contacting NCRR Program Staff.

Federal Grant Title:	Institutional Clinical and Translational Science Award (U54)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-RM-09-019
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.310
CFDA Descriptions:	Trans-NIH Research Support
Current Application Deadline:	Jun 01, 2010
Original Application Deadline:	Jun 01, 2010
Posted Date:	Aug 27, 2009
Creation Date:	Aug 27, 2009
Archive Date:	Jul 02, 2010
Total Program Funding:	$116,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education - Private institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: This FOA is limited to current Clinical and Translational Science Award (CTSA) awardees and current or new collaborators. Because the Institutional CTSA program is focused on the development of a rigorous and robust academic discipline of clinical and translational science, the applicant institution(s) must include a graduate school accredited to award higher degrees in clinical research. Examples of acceptable higher degrees include MS and PhD in topics such as Clinical Research, Public Health, Pharmacology, Nursing and Epidemiology. Partnerships among schools of medicine, dentistry, nursing, pharmacy, osteopathy, public health, engineering and other clinically-related institutions are strongly encouraged, as is the inclusion of other relevant clinical research entities and organizations. The CTSA is expected to form an integrated institutional home that includes faculty committed to developing the discipline of clinical and translational science that will transcend multiple departments, schools, clinical and research institutes and hospitals. Therefore, an institution may submit only a single application in response to this FOA. Multiple applications from different divisions, faculties, centers, schools, etc. of the same university or medical school will be returned without further consideration by the NIH. Potential applicants whose existing and long-term affiliations will be disrupted by this rule must contact NIH Program Staff to determine whether they may be eligible for a waiver of the restriction. Foreign institutions are not allowed to apply for this program. Domestic institutions may use CTSA resources to support the foreign activities of projects that receive primary funding from DHHS. These activities are permitted under the UL1 and KL2 components of the CTSA only and may not include the pre-doctoral TL1 component. Appropriate clearances, a mentoring plan for any foreign training and approval by NIH Program Staff are required before the use of CTSA resources begins. Applications from ineligible institutions will not be reviewed. Applicants are encouraged to demonstrate significant institutional commitment when it is offered.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial No...; • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...; • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional); • NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); • NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional); • Using Metabolomics to Investigate Biological Pathways and Networks (R01); • Assay Development for High Throughput Molecular Screening (R21); • Membrane Protein Production and Structure Determination (R01)
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...